Group 1 - The company, Fujian Cosunter Pharmaceutical Co., Ltd., plans to issue A-shares to specific investors, with the proposal approved by the board and shareholders [2][3] - The issuance will target no more than 35 specific investors, including qualified institutional investors and individuals, with all subscriptions to be made in cash [3][4] - The pricing for the shares will be based on the average trading price over the 20 trading days prior to the pricing date, set at no less than 80% of that average [4] Group 2 - The total number of shares to be issued will not exceed 47,780,100, representing no more than 30% of the company's total share capital prior to the issuance [5] - The company aims to raise up to 976.87 million yuan, with funds allocated primarily for innovative drug research and development, traditional Chinese medicine industrialization, and working capital [5] - The company will initially use self-raised funds for projects until the raised funds are available, and if the actual net amount raised is less than planned, adjustments will be made based on project priorities [5] Group 3 - After the issuance, the shares subscribed by investors will be subject to a six-month lock-up period [6] - The issuance will not change the controlling shareholder or the actual controller of the company, nor will it affect the distribution of shares in a way that violates listing conditions [6] - The company has committed to measures to compensate for any dilution of immediate returns resulting from the issuance [6] Group 4 - The company has experienced continuous losses, with net profits of -132.18 million yuan, -354.23 million yuan, -199.54 million yuan, and -30.42 million yuan in recent periods, primarily due to increased R&D investments and price declines from centralized procurement policies [10][11] - The company is focusing on innovative drug development, which typically involves high costs and long timelines, and faces risks related to market acceptance and competition [9][10] - The company has established itself as a well-known player in the antiviral drug market, particularly in hepatitis B treatment, with a product portfolio that includes generics and innovative drugs [14]

Company Overview - Fujian Guangshentang Pharmaceutical Co., Ltd. was established as a joint-stock company from the transformation of Fujian Guangshentang Pharmaceutical Co., Ltd. [1] - The company is located in Fujian Province, with its registered capital and paid-in capital both amounting to 159.267 million RMB as of December 31, 2024 [3]. Business Nature and Activities - The company operates in the pharmaceutical manufacturing industry, with a business scope that includes drug production, wholesale, retail, food sales, health food production, and drug import/export [3]. - The company has 13 subsidiaries included in its consolidated financial statements, with an increase of 2 subsidiaries compared to the previous period [3]. Financial Reporting - The financial statements were approved by the board of directors on April 16, 2025 [4]. - The company prepares its financial statements based on actual transactions and events, adhering to the accounting standards set by the Ministry of Finance [4]. Financial Condition - The company has experienced continuous losses over the past three years due to significant R&D investments, with a consolidated asset-liability ratio of 72.42% as of December 31, 2024 [4]. - The company has a total of 300 million RMB in borrowings, with available cash of 143 million RMB and unused credit lines of 125 million RMB, indicating a strategy to maintain liquidity [4]. Capital Structure - The company issued 17.5 million A-shares in 2015, with 3.5 million shares being transferred and 14 million new shares issued [1]. - In 2021, the company issued 18.777 million shares to specific investors, with the new shares listed on July 9, 2021 [1]. Stock Option Plan - The company approved a stock option incentive plan, allowing 22 eligible participants to exercise 798,000 stock options at a price of 31.23 RMB per share, with a total exercise amount of approximately 15.3 million RMB [2].

Core Viewpoint - Fujian Guangshentang Pharmaceutical Co., Ltd. is preparing to issue A-shares to specific investors in 2025, with the aim of raising funds for various projects, including innovative drug research and traditional Chinese medicine industrialization. Group 1: Issuance Details - The company plans to issue no more than 47,780,100 A-shares, which will not exceed 30% of the total share capital before the issuance [12][14] - The total amount to be raised is not more than 976.87 million yuan, with funds allocated to innovative drug research, traditional Chinese medicine industrialization, and working capital [15] - The issuance will be conducted through a specific object issuance method, targeting up to 35 specific investors, including qualified institutional investors and natural persons [12][15] Group 2: Legal Compliance and Approval - The board of directors and the shareholders' meeting have approved the issuance plan, ensuring compliance with the Company Law and the company's articles of association [11][16] - The issuance is subject to approval from the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission [16][17] - The company has conducted thorough legal due diligence to ensure compliance with relevant laws and regulations [6][24] Group 3: Company Structure and Independence - Fujian Guangshentang Pharmaceutical is a legally established joint-stock company with independent operations, assets, and financial management [24][26] - The company has no business relationships with its controlling shareholders that would compromise its independence [25][26] - The controlling shareholder, Aohua Group, holds 17% of the shares, while the actual controllers have a combined voting power of 40.89% [27][28] Group 4: Financial and Operational Integrity - The company has maintained a clean legal record, with no significant violations or administrative penalties in the past three years [20][21] - The financial statements have been audited and comply with accounting standards, ensuring transparency and reliability [20][21] - The company has established a robust governance structure, with independent management and operational capabilities [25][26]

关于向特定对象发行股票申请获得深圳证券交易所 受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 福建广生堂药业股份有限公司（以下简称"公司"）于 2025 年 5 月 23 日收 到深圳证券交易所（以下简称"深交所"）出具的《关于受理福建广生堂药业股 份有限公司向特定对象发行股票申请文件的通知》（深证上审〔2025〕68 号）。 深交所对公司报送的向特定对象发行股票的申请文件进行了核对，认为申请文件 齐备，决定予以受理。 公司本次向特定对象发行股票事项尚需通过深交所审核，并获得中国证券监 督管理委员会（以下简称"中国证监会"）同意注册后方可实施，最终能否通过 深交所审核并获得中国证监会作出同意注册的决定及其时间尚存在不确定性。公 司将根据该事项进展情况及时履行信息披露义务，敬请广大投资者谨慎决策，注 意投资风险。 特此公告。 福建广生堂药业股份有限公司董事会 证券代码：300436 证券简称：广生堂 公告编号：2025047 福建广生堂药业股份有限公司 1 2025 年 5 月 23 日 ...

证券简称：广生堂 证券代码：300436 福建广生堂药业股份有限公司 Fujian Cosunter Pharmaceutical Co., Ltd. （福建省宁德市柘荣县富源工业园区 1-7 幢） 2025 年度向特定对象发行 A 股股票 募集说明书 （申报稿） 保荐人（主承销商） 中国（上海）自由贸易试验区浦明路 8 号 二〇二五年五月 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票募集说明书 发行人声明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露 资料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及 完整性承担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财 务会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与 之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由 发行人自行负责，投资者自主判断 ...

国联民生证券承销保荐有限公司 关于 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票 之 上市保荐书 保荐机构（主承销商） 2025 年 5 月 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票上市保荐书 国联民生证券承销保荐有限公司 关于福建广生堂药业股份有限公司 2025年度向特定对象发行A股股票 之上市保荐书 深圳证券交易所： 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"、"保荐 机构"）接受福建广生堂药业股份有限公司（以下简称"广生堂"、"公司"或 "发行人"）的委托，担任广生堂本次向特定对象发行 A 股股票的保荐机构。 国联民生承销保荐及其保荐代表人根据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司 证券发行注册管理办法》（以下简称"《注册管理办法》"）《证券发行上市保 荐业务管理办法》（以下简称"《保荐管理办法》"）等法律法规和中国证券监 督管理委员会（以下简称"中国证监会"）、深圳证券交易所（以下简称"深交 所"）的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、行业 ...

国联民生证券承销保荐有限公司 关于 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票 之 发行保荐书 保荐机构（主承销商） 2025 年 5 月 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票发行保荐书 国联民生证券承销保荐有限公司 关于福建广生堂药业股份有限公司 2025年度向特定对象发行A股股票之发行保荐书 深圳证券交易所： 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"、"保荐 机构"）接受福建广生堂药业股份有限公司（以下简称"广生堂"、"公司"或 "发行人"）的委托，担任广生堂本次向特定对象发行 A 股股票的保荐机构。 国联民生承销保荐及其保荐代表人根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市 公司证券发行注册管理办法》（以下简称"《注册管理办法》"）《证券发行上市 保荐业务管理办法》（以下简称"《保荐管理办法》"）等法律法规和中国证券 监督管理委员会（以下简称"中国证监会"）、深圳证券交易所（以下简称"深 交所"）的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、行 业 ...

国浩律师（上海）事务所 关于 福建广生堂药业股份有限公司 法律意见书 2025 年度向特定对象发行 A 股股票 之 上海市山西北路 99 号苏河湾中心 25-28 层 邮编：200085 25-28/F, Suhe Centre, No.99 North Shanxi Road, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二〇二五年五月 | 释 义 3 | | --- | | 第一节 引 言 7 | | 一、律师事务所及律师简介 7 | | 二、出具法律意见书涉及的主要工作过程 8 | | 三、法律意见书的申明事项 9 | | 第二节 正 文 11 | | 一、本次发行上市的批准和授权 11 | | 二、发行人本次发行上市的主体资格 14 | | 三、本次发行上市的实质条件 15 | | 四、发行人的设立 18 | | 五、发行人的独立性 18 | | 六、发起人或股东（实际控制人） 20 | | 七、发行人的股本及演变 21 | ...

福建广生堂药业股份有限公司 审计报告 德皓审字[2025]00000894 号 北京德皓国际会计师事务所(特殊普通合伙) BeijingDehaoInternationalCertifiedPublicAccountants(LimitedLiabilityPartnership) 您可使用手机"扫一扫"或8-7-_此码用于证明该审计报告是否由具有执业许可的会计师事务所出 您可使用手机"扫一扫"或8-7-_1注册会计师行业统一监管平台（http://ace.mof.gov.cn）"进行查 报告编码:京25PMY0D7RS 福建广生堂药业股份有限公司 审计报告及财务报表 审计 报告 德皓审字[2025]00000894号 福建广生堂药业股份有限公司全体股东: 一、审计意见 我们审计了福建广生堂药业股份有限公司(以下简称广生堂公司) 财务报表,包括2024年12月31日的合并及母公司资产负债表,2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公 司股东权益变动表以及相关财务报表附注。 (2024年1月1日至 2024年12月31日止） | 目录 | 页次 | | --- | --- | | 审 ...

证券代码：300436 证券简称：广生堂 公告编号：2025046 福建广生堂药业股份有限公司 关于利托那韦片获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 近日，福建广生堂药业股份有限公司（以下简称"公司"）创新药控股子公 司福建广生中霖生物科技有限公司收到国家药品监督管理局核准签发的关于公 司利托那韦片的《药品注册证书》，将进一步提升公司在抗病毒领域的竞争力。 现将有关事项公告如下： 一、药品注册证书基本信息 药品名称：利托那韦片 剂型：片剂 规格：100mg 药品批准文号：国药准字 H20254135 上市许可持有人：福建广生中霖生物科技有限公司 生产企业：福建广生堂药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品相关情况 利托那韦是一种拟肽类 HIV-1 蛋白酶抑制剂。本次获批利托那韦片适应症， 是适用于与其它抗反转录病毒药物联合用药，治疗成人和 2 岁及 2 岁以上儿童的 人类免疫缺陷病毒-1(Human Immunodefic ...